AMTD IDEA Group's Controlling Shareholder, Directors and Executive Officers Enter into Voluntary Lock-up on Holdings
PARIS, NEW YORK and SINGAPORE, April 8, 2026 /PRNewswire/ -- AMTD IDEA Group ("AMTD IDEA Group") (NYSE: AMTD; SGX: HKB), a NYSE and SGX-ST dual-listed company and a subsidiary of AMTD Group Inc. ("AMTD Group"), today announced that AMTD Group and...
NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical...
Applied Intuition and LG Innotek Enter Strategic Partnership to Advance Autonomous Vehicle Development
OEMs will now have a faster path to production-ready autonomy using camera sensors, real-world testing and simulation SUNNYVALE, Calif. and SEOUL, South Korea, March 30, 2026 /PRNewswire/ -- Applied Intuition, Inc. and LG Innotek today announced a...
C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China
CHENGDU, China and JANESVILLE, Wis., March 26, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, today announced the execution of a Master Radioisotope Supply Agreement with SHINE Technologies, LLC...
TelkomMetra Streamlines Business Portfolio, AdMedika Group Poised to Enter a New Growth Phase on Regional Level Under Fullerton Health
A Strategic divestment steps to strengthen the fundamentals of TelkomGroup as the main holding and focus on the core business of digital and telecommunications JAKARTA, Indonesia, March 9, 2026 /PRNewswire/ -- PT Multimedia Nusantara (TelkomMetra),...
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. Antengene will receive USD 80 million of upfront...
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide...
BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody –drug conjugate (ADC) to enter clinical development. BioDlink enabled IND...
AITO and ADM Enter into Strategic Partnership, Marking a New Chapter in the Global Expansion of Intelligent Luxury
CHONGQING, China, Feb. 6, 2026 /PRNewswire/ -- AITO, China's luxury intelligent vehicle brand, has officially signed a strategic cooperation agreement with Performance Plus Motors (subsidiary of Abu Dhabi Motors), a leading luxury automotive dealer...
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an...